# Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

Source: https://onco.cc/trials/nct06735144/  
OnCo record `nct06735144` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of FH-006 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT06735144 by Jiangsu HengRui Medicine Co., Ltd., with 200 participants planned, started 2024-12-23 and due to reach its primary completion in 2027-12. Interventions recorded: FH-006.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06735144
- Phase: 1/2
- Setting: A Multicenter, Open Label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of FH-006 for Injection in Patients With Malignant Solid Tumors
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT06735144: https://clinicaltrials.gov/study/NCT06735144

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06735144.json